CLL patients with high-risk cytogenetics are known to have poor prognosis and limited therapeutic options. Lenalidomide – an immunomodulator with a similar chemical proﬁle to thalidomide – has demonstrated some clinical beneﬁt for these patients.
A recent study, published in the January issue of Leukemia and Lymphoma was conducted to determine the activity of the lenalidomide among patients with high-risk CLL. The patients received lenalidomide for 21 days of a 4-week treatment cycle. Overall response rate among patients with high-risk disease was 38%. Nineteen percent of the patients achieved a complete response. Median progression-free survival was 12.1 months. Demonstrating that responses with lenalidomide were durable, the 2-year estimated survival probability was 58%. The study has shown that the drug is a viable option for this patient population who have historically seen few options for therapy.